Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.62 |
| ▸ | FABP1 | P07148 | 4/20 | 0.56 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.55 |
| ▸ | FABP4 | P15090 | 1/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20859080 | 1.00 | NR1H4 (0.62) | NR1H4FABP1HSD17B13FABP4GPBAR1 | |
| SCHEMBL20859067 | 0.93 | NR1H4 (0.58) | NR1H4FABP1FABP4 | |
| SCHEMBL20859126 | 0.93 | NR1H4 (0.60) | NR1H4FABP1HSD17B13FABP4GPBAR1 | |
| SCHEMBL20859154 | 0.93 | NR1H4 (0.55) | NR1H4FABP1HSD17B13GPBAR1 | |
| SCHEMBL17856116 | 0.91 | NR1H4 (0.59) | NR1H4FABP1FABP4 | |
| SCHEMBL21264346 | 0.90 | NR1H4 (0.62) | NR1H4FABP1HSD17B13FABP4GPBAR1 | |
| SCHEMBL21703707 | 0.90 | NR1H4 (0.62) | NR1H4FABP1HSD17B13FABP4GPBAR1 | |
| SCHEMBL21244300 | 0.89 | NR1H4 (0.59) | NR1H4FABP1HSD17B13FABP4GPBAR1 | |
| SCHEMBL21244299 | 0.89 | NR1H4 (0.59) | NR1H4FABP1HSD17B13FABP4GPBAR1 | |
| SCHEMBL25515551 | 0.88 | NR1H4 (0.61) | NR1H4FABP1HSD17B13FABP4GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751874-B2 | Hydroxy containing FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885FABP1 20/4885HSD17B13 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.